Loading organizations...
Hidragon Capital operates as an equity investment management firm, primarily focused on sourcing and executing long-term value investments across various sectors. The company functions as a venture capital entity, deploying capital into promising enterprises. Its strategic approach emphasizes identifying robust opportunities to build sustainable value over extended periods, providing financial backing and strategic support to its portfolio.
The firm was established in 2011, originating in Shanghai, China. While specific details regarding its foundational insight are not publicly elaborated, the establishment reflects a commitment to leveraging expertise within the regional investment landscape. Key professionals, such as Partner Ning Lei, bring backgrounds in areas like pharmacokinetics and biotech investment, suggesting a pedigree aligned with specialized industry analysis.
Hidragon Capital serves a range of companies seeking growth capital and strategic partnership through equity investment. The firm manages various venture funds, deploying resources to foster innovation and expansion within its portfolio. Its overarching vision centers on being a pivotal partner in the enduring success of its investees, driving sustained development and creating significant long-term value within the broader market.
Hidragon Capital has 3 tracked investments across 3 companies. The latest tracked deal is $120.0M Series C in EpimAb Biotherapeutics in March 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 1, 2021 | EpimAb Biotherapeutics | $120.0M Series C | Tony Rong, Sungwon Song | Cventures, Adrian Cheng, Cormorant Asset Management, Decheng Capital, Hony Capital, Octagon Capital, Sdic Fund, ShangBay Capital, Sherpa Healthcare Partners, Yanchuang Capital |
| Dec 30, 2018 | GenFleet Therapeutics | $17.5M Series A | Ally Bridge Group | CSPC Pharma, Sinopharm Capital, TF Capital |
| Jan 9, 2017 | Ascentage Pharma | $72.1M Series B | Future Industry Ventures | Efung Capital, KIP Capital, Oriza Ventures, Shiyu Capital, YuanMing Capital |